Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases.
Company Details
- Founded
- 2021
- Address
- Parc Eurasanté, Lille,nord 59120,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://genvadetherapeutics.com/
- Keywords
- small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, Duchenne.
- HQ
- Lille, Nord
Genvade Therapeutics Questions
Genvade Therapeutics's website is https://genvadetherapeutics.com/
Genvade Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/genvade-therapeutics
Genvade Therapeutics's industry is
Biotechnology Research
Genvade Therapeutics's top competitors are
4p-Pharma,
Occigen,
Stemselect,
Voltify,
Celeos Sas,
Bifinove,
Fibronox, Inc.,
Biothelis,
Lipofabrik,
Eurabiotech.
Genvade Therapeutics's categories are Biotechnology Research
Genvade Therapeutics's founding year is 2021
